Initial experience with temsirolimus in 2nd-, 3rd- and 4th-line therapy for metastatic renal cell cancer: Good Clinical response

Urologia Internationalis

Volumn 86, Issue 3, 2011, Pages 256-260

  Kuru, Timur Hasan ^a   Huber, Johannes ^a   Hatiboglu, Gencay ^a   Wagener, Nina ^a   Pahernik, Sascha ^a   Hadaschik, Boris ^a   Hohenfellner, Markus ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

2nd line therapy; Metastatic renal cell carcinoma; Pneumonitis; Temsirolimus

Indexed keywords

EVEROLIMUS; SORAFENIB; SUNITINIB; TEMSIROLIMUS;

AGED; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER REGISTRY; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DISEASE SEVERITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; HUMAN; KIDNEY CANCER; MALE; METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; SIDE EFFECT; SYSTEMIC THERAPY; TREATMENT RESPONSE; WEIGHT REDUCTION;

AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; HUMANS; KIDNEY NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MEDICAL ONCOLOGY; NEOPLASM METASTASIS; PNEUMONIA; PROSPECTIVE STUDIES; REGISTRIES; SIROLIMUS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 79955123796     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000322545     Document Type: Article

References (12)

1. Ljungberg B, Cowan NC, Hanbury DC, Hora M, Kuczyk MA, Merseburger AS, Patard JJ, Mulders PF, Sinescu IC: EAU Guidelines on Renal Cell Carcinoma: The 2010 Update. Eur Urol 2010; 58: 398-406.
2. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356: 2271-2281. (Pubitemid 46849157)
3. Bellmunt J, Szczylik C, Feingold J, Strahs A, Berkenblit A: Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features. Ann Oncol 2008;19: 1387-1392.
4. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M: Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002; 20: 289-296. (Pubitemid 34032623)
5. Karnofsky DA, Burchenal JH: The clinical evaluation of chemotherapeutic agents in cancer; in MacLeod CM (ed): Evaluation of Chemotherapeutic Agents. New York, Columbia University Press, 1949, p 196.
6. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-247.
7. Jafri M, Douis H, Porfiri E: Prolonged response to temsirolimus in a pre-treated patient with metastatic renal cell carcinoma and poor performance status. Clin Oncol (R Coll Radiol) 2008; 20: 657-658.
8. Vickers MM, Choueiri TK, Rogers M, Percy A, Finch D, Zama I, Cheng T, North S, Knox JJ, Kollmannsberger C, McDermott DF, Rini BI, Heng DY: Clinical outcome in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factortargeted therapy. Urology 2010; 76: 430-434.
9. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grunwald V, Thompson JA, Figlin RA, Hollaender N, Kay A, Ravaud A: Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 2010; 116: 4256-4265.
10. Maroto P, Dutcher J, White C, Krygowski M, Cincotta M, et al: A radiographic findings of drug-induced pneumonitis and clinical correlation in patients with advanced renal cell carcinoma treated with temsirolimus. Eur J Cancer 2009; 7:426.
11. Duran I, Siu LL, Oza AM, Chung T-B, Sturgeon J, Townsley CA, Pond GR, Seymour L, Niroumand M: Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus. Eur J Cancer 2006; 42: 1875-1880. (Pubitemid 44149096)
12. Rodriguez-Pascual J, Cheng E, Maroto P, Duran I: Emergent toxicities associated with the use of mTOR inhibitors in patients with advanced renal carcinoma. Anticancer Drugs 2010; 21: 478-486.